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INTRODUCTION
Antineutrophil cytoplasmic antibody (ANCA)-associated vas-
culitis (AAV) is defined as a group of vasculitides predomi-
nantly affecting small vessels including capillaries, venules, 
arterioles, and small arteries, according to the guidelines set 
by the 2012 Chapel Hill Consensus Conferences on Nomen-
clature of Vasculitis (2012 CHCC definitions).1 Unlike the 1994 
CHCC definitions, the 2012 guidelines divided small vessel 
vasculitis (SVV) into two groups of AAV and immune complex 
SVV.2 Therefore, the 2012 CHCC definition was the first to offi-
cially categorise SVV based on the detection of ANCA.1 AAV 
consists of three subtypes: microscopic polyangiitis (MPA), 
granulomatosis with polyangiitis (GPA), and eosinophilic gran-
ulomatosis with polyangiitis (EGPA). The frequencies and clini-
cal manifestations differ subtly across these three subtypes. 
Glomerulonephritis occurs very commonly in MPA, often in 
GPA, and occasionally in EGPA. Pulmonary capillaritis is com-
monly found in patients with MPA, but less so in those with 
GPA and EGPA. Moreover, GPA often induces development of 
granulomas in the upper and lower respiratory tracts, while 
EGPA is characterised by the occurrence of three allergic, clini-
Controlling Nutritional Status Score is Associated 
with All-Cause Mortality in Patients with Antineutrophil 
Cytoplasmic Antibody-Associated Vasculitis
Sung Soo Ahn1, Seung Min Jung1, Jason Jungsik Song1,2, Yong-Beom Park1,2, and Sang-Won Lee1,2
1Division of Rheumatology, Department of Internal Medicine, and 2Institute for Immunology and Immunological Disease, 
Yonsei University College of Medicine, Seoul, Korea.
Purpose: The controlling nutritional status (CONUT) score was developed to detect undernutrition in patients. Here, we investi-
gated whether the CONUT score estimated at diagnosis could help predict poor outcomes [all-cause mortality, relapse, and end-
stage renal disease (ESRD)] of antineutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV).
Materials and Methods: We retrospectively reviewed and collated data, including baseline characteristics, clinical manifestations 
(to calculate AAV-specific indices), and laboratory results, from 196 newly diagnosed AAV patients. Serum albumin, peripheral 
lymphocyte, and total cholesterol levels (at diagnosis) were used to calculate CONUT scores.
Results: In total, 111 patients had high CONUT scores (≥3), which showed higher frequency of myeloperoxidase-ANCA and 
ANCA positivity, and demonstrated higher AAV-specific indices. The optimal cut-offs of CONUT score (at diagnosis) for predicting 
all-cause mortality and ESRD were ≥3.5 and ≥2.5, respectively. Patients with CONUT scores higher than the cut-off at diagnosis ex-
hibited lower cumulative and ESRD-free survival rates compared to those with lower scores than the cut-off. In multivariable anal-
yses, diabetes mellitus [hazard ratio (HR): 4.394], five-factor score (HR: 3.051), and CONUT score ≥3.5 (HR: 4.307) at diagnosis were 
independent predictors of all-cause mortality, while only serum creatinine (HR: 1.714) was an independent predictor of ESRD oc-
currence.
Conclusion: CONUT score at diagnosis is associated with all-cause mortality in AAV patients.
Key Words:  ANCA-associated vasculitis, CONUT score, all-cause mortality, predictor
Original Article 
pISSN: 0513-5796 · eISSN: 1976-2437
Received: August 29, 2019   Revised: October 19, 2019
Accepted: October 29, 2019
Corresponding author: Sang-Won Lee, MD, PhD, Division of Rheumatology, De-
partment of Internal Medicine, Institute for Immunology and Immunological Dis-
ease, Yonsei University College of Medicine, 50-1 Yonsei-ro, Seodaemun-gu, Seoul 
03722, Korea.
Tel: 82-2-2228-1987, Fax: 82-2-393-6884, E-mail: sangwonlee@yuhs.ac
•The authors have no potential conflicts of interest to disclose.
© Copyright: Yonsei University College of Medicine 2019
This is an Open Access article distributed under the terms of the Creative Com-
mons Attribution Non-Commercial License (https://creativecommons.org/licenses/
by-nc/4.0) which permits unrestricted non-commercial use, distribution, and repro-
duction in any medium, provided the original work is properly cited.
Yonsei Med J 2019 Dec;60(12):1164-1173
https://doi.org/10.3349/ymj.2019.60.12.1164
1165
Sung Soo Ahn, et al.
https://doi.org/10.3349/ymj.2019.60.12.1164
cal manifestations: asthma, peripheral eosinophilia, and devel-
opment of eosinophil-rich granulomas of the respiratory tract.1
Generally, occurrence of all-cause mortality, relapse (or re-
fractory illness in case of GPA), and end-stage renal disease 
(ESRD) are considered poor outcomes of AAV, with all-cause 
mortality reported to occur 2.7 times more frequently in affected 
patients, as compared to the general population.3 So far, sev-
eral baseline predictors or those encountered at the time of di-
agnosis have been suggested, which can be used to prognosti-
cate poor outcomes in AAV patients. Myeloperoxidase (MPO)-
ANCA positivity at diagnosis was found to be associated with 
high all-cause mortality and low relapse frequency.4 Meanwhile, 
MPO-ANCA positivity, old age, and an estimated low glomeru-
lar filtration rate were proven to predict diminished renal func-
tion after 3 years with AAV.5 Furthermore, the clinical features 
and course of AAV may exhibit differences based on the eth-
nicity of the affected patients. A previous study reported that 
Japanese patients with GPA were older at disease onset and 
showed lower proteinase 3 (PR3)-ANCA positivity, milder re-
nal dysfunction, and more frequent respiratory involvement 
than those diagnosed with AAV in the United Kingdom.6 An-
other study also reported that MPA phenotypes were different 
in Europe compared to those presenting in Japan. However, 
both cumulative survival and renal-sparing rates were not dif-
ferent between European and Japanese patients.7 We previ-
ously aimed to identify the clinical significance of certain in-
dependent baseline factors in predicting the poor outcomes of 
AAV, while considering these ethnic differences in disease pre-
sentation. All-cause mortality has been shown to be positively 
and inversely associated with the C-reactive protein (CRP)-to-
serum albumin and the albumin-to-globulin ratios at diagno-
sis, respectively,8,9 while AAV-relapse has been found to be asso-
ciated with the neutrophil-to-lymphocyte ratio, delta neutrophil 
index, and systemic immune-inflammation index at diagno-
sis.10-12 Similarly, development of ESRD is known to be associ-
ated with systemic immune-inflammation and low levels of 
complement 3 at diagnosis.12,13 While various baseline predic-
tors of outcomes of AAV have been suggested, there is no ab-
solute predictor or method of evaluation at the time of diagno-
sis to help prognosticate outcomes, which has significant 
clinical implications.
The controlling nutritional status (CONUT) score was de-
veloped for the assessment of nutritional status, in order to 
enable an early detection of undernutrition in hospitalized 
patients.14 A preoperative low CONUT score is known to indi-
cate poor prognosis in patients with solid cancers.15 CONUT 
score was also reported to indicate inflammation and was 
shown to predict poor outcomes in patients with inflammatory 
systemic diseases, including heart failure and acute myocar-
dial infarction.16,17 It was demonstrated that several nutritional 
indices assessed at baseline could help predict the poor out-
comes of AAV. Therefore, we theorized that the CONUT score 
(also a nutritional index) estimated at the time of diagnosis, 
could be utilized to prognosticate poor outcomes of AAV dur-
ing follow-up. There have been no prior studies of CONUT 
score in this context. Thus, in this study, we investigated wheth-
er the CONUT score assessed during AAV diagnosis could help 
the treating clinician predict poor disease outcomes, such as all-
cause mortality, relapse, and ESRD development, during sub-
sequent follow-ups of affected patients.
MATERIALS AND METHODS
Patients
We retrospectively reviewed the medical records of 196 patients 
with AAV who had not received immunosuppressive therapy 
before disease diagnosis (immunosuppressive therapy-naïve). 
All included patients had been diagnosed with AAV for the first 
time at the Department of Internal Medicine, Yonsei Univer-
sity College of Medicine, Severance Hospital, from October 
2000 to December 2018. Their well-documented medical re-
cords were utilized to collate and assess clinical data includ-
ing disease manifestations, laboratory results, and AAV-specif-
ic indices, such as the Birmingham vasculitis activity score 
(BVAS) and the five-factor score (FFS), recorded at the time of 
diagnosis. As revised BVAS for GPA has a different system of 
weightage compared to the original BVAS scoring method, we 
evenly applied the latter system (even in patients with GPA) to 
unify the scoring system applied in this study.18-20 The patients 
were all reclassified into AAV subtypes according to the 2007 
European Medicines Agency algorithm for AAV, and on the 
basis of descriptions provided by the 2012 CHCC definitions. 
Furthermore, the included patients had no serious comorbidi-
ties that could mimic AAV at diagnosis, as identified in the 10th 
revised International Classification Diseases (ICD-10). This 
study was approved by the Institutional Review Board (IRB) of 
Severance Hospital (4-2017-0673), which also waived the re-
quirement of obtaining written informed consent from the 
patients, as this was a retrospective study.
Clinical data and routine laboratory results at diagnosis 
We collated demographic data, including age and sex of the pa-
tients, and reviewed the test results for the detection of ANCA 
that were recorded at the time of diagnosis. Comorbidities, in-
cluding diabetes mellitus (DM) and hypertension (HTN), were 
also assessed at baseline. Clinical data at diagnosis were col-
lected based on the items in BVAS and FFS. Laboratory results 
at diagnosis, including blood (white blood cell, lymphocyte, and 
platelet) counts, as well as levels of haemoglobin, prothrombin 
time, fasting glucose, blood urea nitrogen (BUN), creatinine, 
total serum protein, serum albumin, aspartate aminotransfer-
ase (AST), alanine aminotransferase (ALT), total cholesterol, 
erythrocyte sedimentation rate (ESR), and CRP, were also ob-
tained.
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Calculation of CONUT score at diagnosis 
The CONUT score is calculated based on serum albumin, lym-
phocyte count (in peripheral blood), and total cholesterol lev-
els. Values for each variable are divided into four ranges, and 
sequential points are assigned to each range: 1) for albumin 
(mg/L): ≥3.5=0, 3.0–3.4=2; 2.5–2.9=4, and <2.5=6; 2) for lym-
phocyte count (/mm3): ≥1600=0, 1200–1599=1, 800–1199=2, 
and <800=3; 3) for serum total cholesterol (mmol/L): ≥180=0, 
140–179=1, 100–139=2, and <100=3. The sum of these compo-
nent points constituted the total CONUT score, which was used 
to define the level of undernutrition as per the following scale: 
0–1: normal, 2–4: mild, 5–8: moderate, and 9–12: severe. In gen-
eral, a CONUT score ≥3 is defined as a high score.14
Clinical outcomes and immunosuppressive therapies
All-cause mortality, relapse, and ESRD were evaluated as poor 
outcome measures of AAV. All-cause mortality was defined as 
death due to any reason during follow-up, and ESRD was de-
fined as an impairment of renal function requiring dialysis. Re-
lapse was defined as recurrence or new-onset of disease with 
active vasculitis.21 The total follow-up duration was recorded as 
the time-interval from the point of diagnosis of AAV to the last 
visit, to death, to the time of relapse, and to the time of initiation 
of dialysis for the surviving, deceased, relapsed, and ESRD pa-
tients, respectively. We also reviewed the immunosuppressive 
therapies administered in all patients during follow-up, includ-
ing glucocorticoids, cyclophosphamide, rituximab, azathio-
prine, mycophenolate mofetil, tacrolimus, methotrexate, and 
plasma exchange.
Statistical analyses
All statistical analyses were conducted using SPSS software 
(version 23 for Windows; IBM Corp., Armonk, NY, USA). Con-
tinuous variables were expressed as a mean±standard devia-
tion, and categorical variables were expressed as a number 
(percentages). Significant differences between the two groups 
were analysed using the chi-square with Fisher’s exact tests 
and Mann-Whitney test. The optimal cut-off for the score was 
extrapolated by plotting the receiver operator characteristic 
(ROC) curve and estimating the maximised sum of sensitivity 
and specificity. The correlation coefficient was obtained using 
Pearson correlation analysis. The comparison of cumulative 
survival between the two groups was performed using Kaplan-
Meier survival analysis. Multivariate Cox hazard model was 
estimated using variables showing statistical significance in 
the preceding univariate Cox hazard analysis, in order to ob-
tain hazard ratios (HRs). p values<0.05 were considered statis-
tically significant.
RESULTS
Comparison of baseline variables between AAV 
patients with low and high CONUT score at diagnosis
The mean age of 196 AAV patients (106, 50, and 40 patients di-
agnosed with MPA, GPA, and EGPA, respectively) was 56.6 
years; 59 patients were male. The mean follow-up duration 
was 50.3 months. The mean CONUT score at diagnosis was 
3.6. Patients with AAV were divided into two groups: high (de-
fined as ≥3) or low CONUT score; 111 patients were included in 
high-score group. The mean score of AAV patients included in 
the high and low CONUT score groups were 5.7 and 0.9. Patients 
with low CONUT scores exhibited higher frequency of HTN 
compared to those with high CONUT scores. Between patients 
with low CONUT scores and those with high CONUT scores, 
the proportion of EGPA was higher in low CONUT score group 
(28.2% vs. 14.4%, p=0.041), and 60% of EGPA patients had low 
CONUT score. MPO-ANCA (or P-ANCA) was more frequently 
detected in patients with high CONUT scores, whereas ANCA 
negativity was more prevalent in patients with low scores. Pa-
tients with high CONUT scores showed higher mean values of 
BVAS and FFS at diagnosis compared to the rest. Pulmonary 
and renal manifestations were also more frequently observed 
in patients with high CONUT scores than in those with lower 
scores. Furthermore, at diagnosis, patients with high CONUT 
scores exhibited higher white blood cell and platelet counts, 
along with higher values of prothrombin time, fasting glucose, 
BUN, creatinine, ESR, and CRP, while conversely showing lower 
levels of haemoglobin, total serum protein, serum albumin, and 
total cholesterol, compared to those with low CONUT scores 
(Table 1). 
Correlation between CONUT score and continuous 
variables at diagnosis
An assessment of AAV-specific indices at diagnosis showed 
that CONUT score correlated significantly with BVAS (r=0.361, 
p<0.001) and FFS (r=0.377, p<0.001) values. CONUT score 
was also found to correlate positively with the levels of white 
blood cells (r=0.301, p<0.001), platelets (r=0.339, p<0.001), pro-
thrombin time (r=0.491, p<0.001), fasting glucose (r=0.154, p= 
0.031), BUN (r=0.204, p=0.004), AST (r=0.216, p=0.002), ALT 
(r=0.172, p=0.016), ESR (r=0.465, p<0.001), and CRP (r=0.636, 
p<0.001). Conversely, the score correlated negatively with the 
haemoglobin level (r=-0.553, p<0.001) and total serum pro-
tein (r=-0.552, p<0.001) at diagnosis. Since lymphocyte count, 
levels of serum albumin, and total cholesterol were used in 
the calculation of CONUT score, they were not included in the 
correlation analysis (Supplementary Table 1, only online). 
Comparison of follow-up variables between AAV 
patients with low and high CONUT scores
In Table 2, we have summarized a comparison of follow-up 
variables, including clinical outcomes of AAV, and the immu-
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Table 1. Comparison of Variables between AAV Patients with Low and High CONUT Scores at Diagnosis
Variables Total (n=196)
Patients with low 
CONUT scores (n=85)
Patients with high 
CONUT scores (n=111)
p value
Demographic data 
Age at diagnosis (yr) 56.6±14.7 54.2±14.3 58.3±14.8 0.053
Male gender (n, %) 59 (30.1) 23 (27.1) 36 (32.4) 0.416
Follow-up duration (mon) 50.3±47.6 51.7±51.2 49.2±44.9 0.712
Comorbidities (n, %)
Diabetes mellitus 38 (19.4) 20 (23.5) 18 (16.2) 0.201
Hypertension 72 (36.7) 24 (28.2) 48 (43.2) 0.031
Variants of AAV (n, %) 0.041
MPA 106 (54.1) 39 (45.9) 67 (60.4)
GPA 50 (25.5) 22 (25.9) 28 (25.2)
EGPA 40 (20.4) 24 (28.2) 16 (14.4)
ANCA positivity at diagnosis (n, %)
MPO-ANCA or P-ANCA 127 (64.8) 42 (49.4) 85 (76.6) <0.001
PR3-ANCA or C-ANCA 32 (16.3) 12 (14.1) 20 (18.0) 0.464
Both ANCAs 8 (4.1) 1 (1.2) 7 (6.3) 0.072
ANCA negativity 45 (23.0) 32 (37.6) 13 (11.7) <0.001
AAV-specific indices at diagnosis 
BVAS 12.8±6.9 10.6±6.0 14.4±7.1 <0.001
FFS (2009) 1.3±1.0 1.0±0.9 1.5±1.1 <0.001
Clinical manifestations at diagnosis (n, %)
General 84 (42.9) 30 (35.3) 54 (48.6) 0.061
Cutaneous 41 (20.9) 20 (23.5) 21 (18.9) 0.432
Muco-membranous/ocular 13 (6.6) 5 (5.9) 8 (7.2) 0.712
Ear nose throat 78 (39.8) 38 (44.7) 40 (36.0) 0.219
Pulmonary 112 (57.1) 41 (48.2) 71 (64.0) 0.027
Cardiovascular 48 (24.5) 19 (22.4) 29 (26.1) 0.543
Gastrointestinal 10 (5.1) 4 (4.7) 6 (5.4) 0.825
Renal 116 (59.2) 43 (50.6) 73 (65.8) 0.032
Nervous 59 (30.1) 24 (28.2) 35 (31.5) 0.618
Routine laboratory results at diagnosis
White blood cell count (/mm3) 1093.5±4692.4 9272.8±4256.5 10721±4927.3 0.029
Lymphocyte count (/mm3) 1543.5±732.3 1960.5±623.9 1224.1±645.1 <0.001
Haemoglobin (g/dL) 11.4±2.3 12.7±1.9 10.4±2.1 <0.001
Platelet count (×1000/mm3) 332.1±142.9 299.2±119.0 357.4±154.7 0.003
Prothrombin time (INR) 1.0±0.1 1.0±0.1 1.0±0.1 0.001
Fasting glucose (mg/dL) 114.3±42.1 106.1±26.3 120.1±49.7 0.012
BUN (mg/dL) 26.1±23.5 18.9±12.5 30.9±27.9 <0.001
Creatinine (mg/dL) 1.8±2.0 1.4±1.8 2.1±2.1 0.017
Total serum protein (g/dL) 6.6±0.9 7.0±0.7 6.3±0.9 <0.001
Serum albumin (g/dL) 3.5±0.8 4.1±0.4 3.1±0.7 <0.001
AST (IU/L) 23.5±22.8 21.1±10.0 25.4±28.8 0.143
ALT (IU/L) 23.7±33.8 20.3±13.6 26.2±43.1 0.178
Total cholesterol (mg/dL) 173.4±47.0 193.1±38.2 159.1±48.4 <0.001
ESR (mm/hr) 60.0±38.5 46.5±33.1 70.1±39.1 <0.001
CRP (mg/L) 42.7±56.8 14.5±25.6 64.0±6.1 <0.001
CONUT score at diagnosis 3.6±3.0 0.9±0.8 5.7±2.5 <0.001
AAV, ANCA-associated vasculitis; CONUT, controlling nutritional status; MPA, microscopic polyangiitis; GPA, granulomatosis with polyangiitis; EGPA, eosinophilic 
granulomatosis with polyangiitis; ANCA, antineutrophil cytoplasmic antibody; MPO, myeloperoxidase; P, perinuclear; PR3, proteinase 3; C, cytoplasmic; BVAS, 
Birmingham vasculitis activity score; FFS, five-factor score; INR, international normalized ratio; BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, ala-
nine transaminase; ESR, erythrocyte sedimentation rate; CRP, C-reactive protein. 
Values are expressed as mean±standard deviation or number (%) unless otherwise indicated. 
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nosuppressive therapy administered between patients with 
high and low CONUT scores. During follow-up, patients with 
high CONUT scores showed higher frequency of develop-
ment of ESRD than the rest. Glucocorticoids, cyclophospha-
mide, and rituximab had been administered more frequently 
to patients with high CONUT scores compared to those with 
low scores. Moreover, plasma exchange had been performed 
only in patients with high CONUT scores. These results suggest 
that a high CONUT score was indicative of increased AAV ac-
tivity, which required more aggressive immunosuppression.
Cut-offs of CONUT score and cumulative survival rates
The optimal cut-offs of CONUT score estimated at diagnosis 
for predicting all-cause mortality and ESRD occurrence were 
≥3.5 [area under the curve (AUC): 0.680; 95% confidence inter-
val (CI): 0.541, 0.819; sensitivity: 0.700; specificity: 0.631] and 
≥2.5 (AUC: 0.628; 95% CI: 0.535, 0722; sensitivity: 0.758; speci-
ficity: 0.528), respectively. However, an optimal cut-off of CO-
NUT score at diagnosis for predicting relapse could not be de-
termined in this study (Fig. 1). Using these CONUT-score cut-
offs, we investigated the cumulative and ESRD-free survival 
rates during subsequent follow-ups, between AAV patients with 
scores below and above the respective cut-off point at diagno-
sis. First, newly diagnosed AAV patients with baseline CONUT 
scores ≥3.5 exhibited lower cumulative survival rates than 
those who scored <3.5 (p=0.002). Similarly, AAV patients with 
CONUT scores ≥2.5 at diagnosis showed lower cumulative 
ESRD-free survival rate than those who scored <2.5 (p=0.017) 
(Fig. 2). 
Table 2. Comparison of Clinical Outcomes, Comorbidities, and Immunosuppressive Therapies during Follow-Up between AAV Patients with Low and 
High CONUT Scores at Diagnosis
Variables Total (n=196)
Patients with low
CONUT scores (n=85)
Patients with high
CONUT scores (n=111)
p value
Clinical outcomes during follow-up
All-cause mortality (n, %) 20 (10.2) 5 (5.9) 15 (13.5) 0.080
Follow-up duration based on mortality (mon) 50.2±47.4 51.4±50.7 49.2±44.9 0.746
Relapse (n, %) 58 (29.6) 21 (24.7) 37 (33.3) 0.190
Follow-up duration based on relapse (mon) 35.4±41.3 37.9±42.9 33.5±40.1 0.452
ESRD (n, %) 33 (16.8) 8 (9.4) 25 (22.5) 0.020
Follow-up duration based on ESRD (mon) 43.2±45.4 46.1±46.4 41.0±44.6 0.444
Immunosuppressive therapies (n, %)
Glucocorticoid 173 (88.3) 68 (80.0) 105 (94.6) 0.002
Cyclophosphamide 85 (43.4) 22 (25.9) 63 (56.8) <0.001
Rituximab 20 (10.2) 4 (4.7) 16 (14.4) 0.026
Azathioprine 66 (33.7) 25 (29.4) 41 (36.9) 0.269
Mycophenolate mofetil 12 (6.1) 3 (3.5) 9 (8.1) 0.185
Tacrolimus 9 (4.6) 3 (3.5) 6 (5.4) 0.534
Methotrexate 14 (7.1) 9 (10.6) 5 (4.5) 0.101
Plasma exchange 6 (3.1) 0 (0) 6 (5.4) 0.029
AAV, antineutrophil cytoplasmic antibody-associated vasculitis; CONUT, controlling nutritional status; ESRD, end-stage renal disease.
Values are expressed as mean±standard deviation or number (%) unless otherwise indicated.
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Fig. 1. Receiver operator characteristics curve analysis of controlling nutritional status score at diagnosis for predicting occurrence of (A) all-cause mor-
tality, (B) relapse, and (C) end-stage renal disease (ESRD). CI, confidence interval.
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Table 3. Predictors of All-Cause Mortality during Follow-Up in AAV Patients
Variables
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Demographic data 
Age at diagnosis 1.048 1.010, 1.088 0.014
Male gender 0.558 0.228, 1.368 0.202
Comorbidities
Diabetes mellitus 3.476 1.337, 9.040 0.011 4.394 1.457, 13.249   0.009
Hypertension 3.736 1.477, 9.448 0.005
ANCA positivity at diagnosis 2.855 0.808, 10.088 0.103
AAV-specific indices at diagnosis 
BVAS 1.079 1.019, 1.142 0.009
FFS (2009) 3.138 2.006, 4.907 <0.001 3.051 1.613, 5.772 <0.001
Routine laboratory results at diagnosis   
White blood cell count 1.000 1.000, 1.000 0.334
Lymphocyte count 1.000 0.999, 1001 0.876
Haemoglobin 0.795 0.646, 0.978 0.795
Platelet count 1.001 0.998, 1.003 0.692
Prothrombin time 23.548 0.506, 1095.288 0.107
Fasting glucose 1.005 0.996, 1.014 0.282
BUN 1.009 0.998, 1.020 0.109
Creatinine 1.159 0.994, 1.351 0.060
Total serum protein 0.601 0.354, 1.020 0.059
Serum albumin* 0.340 0.181, 0.640 0.001
AST 1.014 1.002, 1.026 0.026
ALT 1.004 0.996, 1.013 0.294
Total cholesterol 0.990 0.979, 1.001 0.066
ESR 1.008 0.997, 1.019 0.139
CRP 1.007 1.001, 1.014 0.034
CONUT score at diagnosis 
CONUT score ≥3.5 4.159 1.586, 10.905 0.004 4.307 1.360, 13.635   0.013
AAV, ANCA-associated vasculitis; HR, hazard ratio; CI, confidence interval; ANCA, antineutrophil cytoplasmic antibody; BVAS, Birmingham vasculitis activity 
score; FFS, five-factor score; BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; ESR, erythrocyte sedimentation rate; CRP, C-re-
active protein; CONUT, controlling nutritional status.   
*Due to multicollinearity between serum albumin and CONUT score, serum albumin was excluded from multivariate Cox hazards model analysis despite a sta-
tistically significant association found in univariate analysis. 
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Univariate and multivariate Cox hazard model analyses 
for all cause-mortality
In univariate analysis of various variables assessed at diagno-
sis, factors such as age, comorbidity of DM, HTN, BVAS, FFS, 
and levels of serum albumin, AST, CRP, and a CONUT score 
≥3.5 were found to be significantly associated with all-cause 
mortality during subsequent follow-up. Due to multicollinear-
ity between serum albumin and CONUT score, the former pa-
rameter was excluded from multivariate Cox hazards model 
analysis, despite its statistical significance in univariate analy-
sis. In multivariate analysis of variables showing statistical sig-
nificance in univariate analysis, DM (HR: 4.394, 95% CI: 1.457, 
13.249), FFS (HR: 3.051, 95% CI: 1.613, 5.772) values, and CO-
NUT scores ≥3.5 (HR: 4.307, 95% CI: 1.360, 13.635) at diagnosis 
were found to be independent predictors of all-cause mortality 
during follow-up (Table 3). 
Univariate and multivariate Cox hazard model analyses 
for ESRD occurrence 
In univariate analysis of variables recorded at diagnosis, factors 
such as comorbidity of HTN, BVAS, FFS, lymphocyte count, 
haemoglobin, BUN, serum creatinine, total serum protein, 
AST, ALT, and a CONUT score ≥2.5 were found to be signifi-
cantly associated with ESRD occurrence during follow-up. Al-
though lymphocyte count is one of the items used to calculate 
CONUT score, since there was no multicollinearity between 
the former parameter and the score, it was included in the mul-
tivariate analysis. In multivariate analysis of variables showing 
statistical significance in univariate analysis, only serum creati-
nine (HR: 1.714, 95% CI: 1.408, 2.085) was determined to be an 
independent predictor of development of ESRD during follow-
up (Table 4). 
Table 4. Predictors of ESRD during Follow-Up in AAV Patients 
Variables
Univariate analysis Multivariate analysis
HR 95% CI p value HR 95% CI p value
Demographic data 
Age at diagnosis  1.009 0.985, 1.034 0.471
Male gender 0.782 0.378, 1.615 0.506
Comorbidities
Diabetes mellitus 1.459 0.656, 3.246 0.355
Hypertension 3.423 1.679, 6.977 <0.001
ANCA positivity at diagnosis 2.595 0.910, 7.401 0.075
AAV-specific indices at diagnosis 
BVAS 1.087 1.036, 1.141 0.001
FFS (2009) 1.943 1.410, 2.679 <0.001
Routine laboratory results at diagnosis   
White blood cell count 1.000 1.000, 1.000 0.848
Lymphocyte count* 0.999 0.999, 1.000 0.023
Haemoglobin 0.668 0.562, 0.793 <0.001
Platelet count 0.997 0.994, 1.000 0.069
Prothrombin time 0.652 0.036, 11.726 0.772
Fasting glucose 1.004 0.997, 1.011 0.248
BUN 1.029 1.022, 1.036 <0.001
Creatinine 1.624 1.476, 1.786 <0.001 1.714 1.408, 2.085 <0.001
Total serum protein 0.529 0.351, 0.796 0.002
Serum albumin 0.662 0.424, 1.034 0.070
AST 0.914 0.858, 0.973 0.005
ALT 0.919 0.873, 0.968 0.001
Total cholesterol 0.997 0.990, 1.005 0.468
ESR 1.004 0.995, 1.012 0.387
CRP 1.002 0.996, 1.007 0.580
CONUT score at diagnosis 
CONUT score ≥2.5 2.532 1.142, 5.616 0.022
ESRD, end-stage renal disease; AAV, ANCA-associated vasculitis; HR, hazard ratio; CI, confidence interval; ANCA, antineutrophil cytoplasmic antibody; BVAS, 
Birmingham vasculitis activity score; FFS, five-factor score; BUN, blood urea nitrogen; AST, aspartate transaminase; ALT, alanine transaminase; ESR, erythrocyte 
sedimentation rate; CRP, C-reactive protein; CONUT, controlling nutritional status.   
*Although lymphocyte count is one of the criteria of CONUT scoring system, it was included in multivariate analysis since no multicollinearity was observed be-
tween lymphocyte count and the score.
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DISCUSSION
In this study, we first demonstrated that the CONUT score es-
timated at diagnosis could predict all-cause mortality in AAV 
patients during follow-up, but it could not be used to prognosti-
cate either relapse or ESRD occurrence. To date, an increased 
rate of all-cause mortality in AAV patients has been reported to 
depend on several baseline factors determined at diagnosis, 
including MPO-ANCA positivity, late-onset AAV, and the CRP-
to-serum albumin and the albumin-to-globulin ratios.8,9,22,23 We 
re-evaluated their clinical correlation to the all-cause mortality 
rate in our study population. In univariate Cox hazards model 
analysis, a newly diagnosed patient’s age (HR: 1.048, p=0.014), 
CRP level (HR: 1.007, p=0.034), and serum albumin level (HR: 
0.340, p=0.001) were found to be individually and significantly 
associated with all-cause mortality during subsequent follow-
up, while MPO-ANCA positivity at diagnosis was not (HR: 1.627, 
p=0.320). However, these factors did not achieve significance 
in multivariate Cox hazards model analysis. The advantage of 
CONUT score is that it consists of three variables, and can thus 
respond flexibly to external influences without undergoing ma-
jor variations. In this study, although the lymphocyte count es-
timated at diagnosis was not found to be associated with all-
cause mortality, the serum albumin level at diagnosis exhibited 
a significant inverse association, while total cholesterol level 
showed a tendency to be negatively associated with all-cause 
mortality. Another advantage of using CONUT score is that we 
could estimate and propose the optimal cut-off points of the 
score for predicting all-cause mortality. In this study, newly di-
agnosed AAV patients with CONUT scores ≥3.5 at diagnosis 
showed a 4.3 times higher rate of mortality compared to those 
with scores <3.5. Moreover, the statistical potential of a CONUT 
score (calculated at diagnosis) ≥3.5 in predicting all-cause mor-
tality was comparable to that of FFS determined at diagnosis. 
Hypercholesterolaemia is well-known to be one of the con-
ventional risk factors for all-cause mortality in the general 
population.24 However, according to the CONUT scoring sys-
tem, higher scores are assigned to patients with lower total cho-
lesterol levels. Thus, there might be discordance in predicting 
all-cause mortality, as the score disregards the conventional 
risk factor of hypercholesterolemia in favour of including only 
hypocholesterolaemia as a CONUT score-elevating parameter. 
However, it is notable that several reports have revealed a U-
shaped (or a non-linear) association between serum total cho-
lesterol levels and all-cause mortality.25,26 Another previous 
study proved that decreased cholesterol or persistently low 
cholesterol levels were associated with a higher risk of mortali-
ty in Korean adults, by explaining how malnutrition associated 
with low levels of high-density lipoprotein-cholesterol is a risk 
factor for non-ischaemic heart disease, and how it might play a 
harmful role by increasing the mortality rate in the general 
population.27 In our univariate Cox hazards model analysis, to-
tal cholesterol did not show a statistically significant associa-
tion (p=0.066) with all-cause mortality. However, it did exhibit 
a tendency to be associated with fatality, and we believe this 
might augment the potential of CONUT score estimated at di-
agnosis for prediction of all-cause mortality.
Various comorbidities, such as DM, HTN, dyslipidaemia, 
and chronic renal disease, could also influence all-cause mor-
tality.24 Of these, dyslipidaemia was substituted by either the 
total cholesterol level or CONUT score, while development of 
chronic renal disease was assessed using serum creatinine lev-
els estimated at the time of diagnosis. However, the aim of this 
study was to discover the significance of baseline clinical man-
ifestations and routine laboratory results (particularly those 
included in CONUT scoring system) in newly diagnosed pa-
tients, for predicting poor outcomes of AAV during follow-up; 
therefore, the contribution of DM and HTN to all-cause mortal-
ity was not a part of frontline-assessment in this study. In addi-
tion, when we conducted multivariate Cox hazards model anal-
ysis, we found that co-existing DM (HR: 4.394, 95% CI: 1.457, 
13.249), FFS (HR: 3.051, 95% CI: 1.613, 5.772), and a CONUT 
score ≥3.5 (HR: 4.307, 95% CI: 1.360, 13.635) could be used to 
meaningfully prognosticate all-cause mortality in AAV patients. 
Therefore, we concluded that the CONUT score calculated at 
diagnosis could help predict all-cause mortality in AAV patients 
during follow-up, in a manner comparable to that of conven-
tional risk factors for mortality in the general population.
In our study, AAV patients with high CONUT scores exhib-
ited higher mean BVAS and FFS compared tos those with low 
CONUT score. We wondered whether CONUT score could be 
used to estimate AAV severity in our patients. We defined se-
vere AAV as that meeting the lower limit of the highest tertile 
of BVAS estimated at diagnosis (which was ≥16), and calculat-
ed the cut-off point of CONUT score at diagnosis for defining 
severe AAV, using an ROC curve. The optimal cut-off CONUT 
score was estimated at 2.5 (AUC: 0.694, 95% CI: 0.616, 0.771, 
sensitivity: 0.746, specificity: 0.528). When we divided the AAV 
patients based on this cut-off point, those with CONUT scores 
≥2.5 exhibited significantly higher risk of having severe AAV 
than those who scored <2.5 (relative risk: 3.279, 95% CI: 1.712, 
6.279). These findings support our theory that CONUT score is 
associated with AAV disease activity. However, this result was 
not included in the main results, as the objective of our study 
was to determine independent prognostic predictors at the time 
of AAV diagnosis.
In addition, more EGPA patients than MPA or GPA patients 
belonged to low CONUT score group. Due to the concern that 
EGPA patients may negatively affect the main results of this 
study, we conducted the univariate and multivariate COX haz-
ards model analyses for all cause-mortality in only patients 
with MPA and GPA again. In multivariate analysis using only 
variables with statistical significance in univariate analysis, 
only CONUT score ≥3.5 (HR 4.345, 95% CI: 1.211, 15.585) was 
an independent predictor of all-cause mortality during follow-
up in MPA and GPA patients (Supplementary Table 2, only on-
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line). Therefore, in real clinical practice, it may be more conve-
nient to apply the cut-off of CONUT score ≥ 3.5 to all variants of 
AAV, including MPA, GPA, and EGPA.
Our study is noteworthy in that we are the first to assess the 
clinical implications of using CONUT score at diagnosis for 
predicting all-cause mortality in AAV patients. Furthermore, 
we have suggested the optimal cut-off points of CONUT score 
calculated in newly diagnosed patients for the prediction of 
all-cause mortality. We calculated the effectiveness of CONUT 
score estimated at the time of diagnosis in patients who had yet 
to receive immunosuppressive therapy, which minimised the 
effect of any therapeutic interventions on the predictive ability 
of this scoring system. However, our study also had several limi-
tations. Firstly, we could not assess variables such as genetic 
factors and daily-food habits, which are known to affect all-
cause mortality. Secondly, we could not perform adjustment 
for confounding factors, e.g. treatment modalities, due to the 
retrospective nature of this study. Thirdly, the mean follow-up 
duration in this study was 50.3 months, which was not long 
enough to be representative of a real clinical setting for this dis-
order. Future prospective studies may be able to provide more 
reliable and validated evidence regarding the potential of CO-
NUT score determined at diagnosis in predicting the outcomes 
of AAV. 
In conclusion, CONUT score calculated at the time of diag-
nosis of AAV is associated with all-cause mortality in affected 
patients. Therefore, we suggest that CONUT score may be uti-
lized as a complementary index to predict eventual AAV out-
comes in clinical practice. 
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